Research & Development
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
23 December 2025 - Clinical-stage immunotherapeutics company Aqualung Therapeutics announced on Monday that it has received approval from the US Food and Drug Administration (FDA) for a Phase 2a study...
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
22 December 2025 -

Biopharmaceutical company AstraZeneca plc (LSE: AZN; Nasdaq: AZN), together with Daiichi Sankyo, announced on Monday that Enhertu...

Shield Therapeutics wins FDA approval to expand ACCRUFeR use to adolescents
22 December 2025 - Shield Therapeutics plc (LSE: STX), a pharmaceutical company that specialisies in iron deficiency, announced on Monday that the US Food and Drug Administration has approved an exten...
ECO Animal Health Group secures EU approval for ECOVAXXIN MS
22 December 2025 - Animal health company ECO Animal Health Group plc (AIM: EAH) reported on Monday that the European Commission has granted EU marketing authorisation for ECOVAXXIN MS, its poultry vac...
Hansa Biopharma submits imlifidase Biologics License Application to FDA
22 December 2025 - Swedish biopharmaceutical company Hansa Biopharma AB (STO:HNSA) announced on Friday that it has submitted a Biologics License Application (BLA) to the US Food and Drug Administratio...
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
22 December 2025 - Biotechnology company T-MAXIMUM Pharmaceutical announced on Sunday that it has received IND clearance from the US Food and Drug Administration (FDA) to commence a Phase II clinical ...